Tenzin Adon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tenzin Adon has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Honnavalli Yogish Kumar
Department of Pharmaceutical Chemistry JSS College of Pharmacy JSS Academy of Higher Education and Research (JSSAHER) Sri Shivarathreeshwara Nagar Mysuru Karnataka 570015 India
4 shared publications Dhivya Shanmugarajan
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagar, Mysuru-570015, Karnataka, India
1 shared publication- Dhivya Shanmugarajan
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Mysore, JSS Academy of Higher Education & Research, Mysore 570 015, Karnataka, India
1 shared publication - Hissana Ather
Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia
1 shared publication - Karen Dsouza
Department of Pharmaceutical Chemistry JSS College of Pharmacy JSS Academy of Higher Education and Research (JSSAHER) Sri Shivarathreeshwara Nagar Mysuru Karnataka 570015 India
1 shared publication Sanyukta Bhattacharya
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, 570015, Karnataka, India; Computer Aided Drug Design Lab, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, 570015, Karnataka, India
1 shared publication
Latest Publications
- 3 March 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (9)
Exploring the Future of Metal‐Based Anticancer Agents: A Comprehensive Review of Ruthenium‐Based Complexes
Ruthenium complexes are gaining recognition in oncology as promising alternatives to the traditionally used platinum‐based anticancer agents. Unlike Pt agents, they can better differentiate between healthy and malignant cells, minimizing adverse side effects. They exhibit advantageous properties such as thermodynamic and kinetic stability, increased water solubility, enhanced cellular absorption, superior selectivity and cytotoxicity for tumors, and decreased toxicity to healthy cells. Ruthenium has been used to make complexes having structural variability and the ability to undergo ligand exchange. Ruthenium complexes are effective against metastatic tumor cells and can interact with cellular components; their significant charges and large cavities allow efficient molecule encapsulation. These complexes are being explored to enhance their efficacy in enzymatic research and targeted therapies. The manifold biochemical properties of ruthenium complexes and their ability to induce tumor cell apoptosis through various signaling pathways make them promising candidates for future anticancer agents. Despite successful testing of some of these complexes in clinical trials, none have been commercially available. Continued research aims to unlock the full potential of ruthenium complexes in cancer treatment. This review covers a few research findings of the past 6 years on the potential of ruthenium complexes ligated with organic moieties as antineoplastic agents.
- 3 March 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (9)
Exploring the Future of Metal‐Based Anticancer Agents: A Comprehensive Review of Ruthenium‐Based Complexes
Ruthenium complexes are gaining recognition in oncology as promising alternatives to the traditionally used platinum‐based anticancer agents. Unlike Pt agents, they can better differentiate between healthy and malignant cells, minimizing adverse side effects. They exhibit advantageous properties such as thermodynamic and kinetic stability, increased water solubility, enhanced cellular absorption, superior selectivity and cytotoxicity for tumors, and decreased toxicity to healthy cells. Ruthenium has been used to make complexes having structural variability and the ability to undergo ligand exchange. Ruthenium complexes are effective against metastatic tumor cells and can interact with cellular components; their significant charges and large cavities allow efficient molecule encapsulation. These complexes are being explored to enhance their efficacy in enzymatic research and targeted therapies. The manifold biochemical properties of ruthenium complexes and their ability to induce tumor cell apoptosis through various signaling pathways make them promising candidates for future anticancer agents. Despite successful testing of some of these complexes in clinical trials, none have been commercially available. Continued research aims to unlock the full potential of ruthenium complexes in cancer treatment. This review covers a few research findings of the past 6 years on the potential of ruthenium complexes ligated with organic moieties as antineoplastic agents.
- 27 January 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 287, 117334
Structural requirements of isoform-specific inhibitors of Akt: Implications in the development of effective cancer treatment strategies
- 27 January 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 287, 117334
Structural requirements of isoform-specific inhibitors of Akt: Implications in the development of effective cancer treatment strategies
- Open Access
Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme
CDK4/6 and aromatase are prominent targets for breast cancer drug discovery and are involved in abnormal cell proliferation and growth. Although aromatase inhibitors have proven to be effective (for example exemestane, anastrozole, letrozole), resistance to treatment eventually occurs through the activation of alternative signaling pathways, thus evading the antiproliferative effects of aromatase inhibitors. One of the evasion pathways is Cylin D-CDK4/6-Rb signaling that promotes tumor proliferation and resistance to aromatase inhibitors. There is significant evidence that the sequential inhibition of both proteins provides therapeutic benefits over the inhibition of one target. The basis of this study objective is the identification of molecules that are likely to inhibit both CDK4/6 and aromatase by computational chemistry techniques, which need further biochemical studies to confirm. Initially, a structure-based pharmacophore model was constructed for each target to screen the sc-PDB database. Consequently, pharmacophore screening and molecular docking were performed to evaluate the potential lead candidates that effectively mapped both of the target pharmacophore models. Considering abemaciclib (CDK4/6 inhibitor) and exemestane (aromatase inhibitor) as reference drugs, four potential virtual hit candidates (1, 2, 3, and 4) were selected based on their fit values and binding interaction after screening a sc-PDB database. Further, molecular dynamics simulation studies solidify the stability of the lead candidate complexes. In addition, ADMET and DFT calculations bolster the lead candidates. Hence, these combined computational approaches will provide a better therapeutic potential for developing CDK4/6-aromatase dual inhibitors for HR+ breast cancer therapy.
Open AccessVirtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme
CDK4/6 and aromatase are prominent targets for breast cancer drug discovery and are involved in abnormal cell proliferation and growth. Although aromatase inhibitors have proven to be effective (for example exemestane, anastrozole, letrozole), resistance to treatment eventually occurs through the activation of alternative signaling pathways, thus evading the antiproliferative effects of aromatase inhibitors. One of the evasion pathways is Cylin D-CDK4/6-Rb signaling that promotes tumor proliferation and resistance to aromatase inhibitors. There is significant evidence that the sequential inhibition of both proteins provides therapeutic benefits over the inhibition of one target. The basis of this study objective is the identification of molecules that are likely to inhibit both CDK4/6 and aromatase by computational chemistry techniques, which need further biochemical studies to confirm. Initially, a structure-based pharmacophore model was constructed for each target to screen the sc-PDB database. Consequently, pharmacophore screening and molecular docking were performed to evaluate the potential lead candidates that effectively mapped both of the target pharmacophore models. Considering abemaciclib (CDK4/6 inhibitor) and exemestane (aromatase inhibitor) as reference drugs, four potential virtual hit candidates (1, 2, 3, and 4) were selected based on their fit values and binding interaction after screening a sc-PDB database. Further, molecular dynamics simulation studies solidify the stability of the lead candidate complexes. In addition, ADMET and DFT calculations bolster the lead candidates. Hence, these combined computational approaches will provide a better therapeutic potential for developing CDK4/6-aromatase dual inhibitors for HR+ breast cancer therapy.
- Open Access
- 1 September 2021
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 11 (47) , 29227-29246
CDK4/6 inhibitors: a brief overview and prospective research directions
The discovery of cyclin-dependent kinases (CDK) and their mechanism in regulating the cell cycle process was considered a game-changer in cancer therapy. Cell cycle arrest and apoptosis were both triggered by their inhibition. The CDK4/6 complex acts as a checkpoint during the cell cycle transition from cell growth (G1) to DNA synthesis (S) phase and its deregulation or overexpression induces abnormal cell proliferation and cancer development. Consequently, targeting CDK4/6 has been proposed as a paradigm shift in the anticancer approach. The design and development of effective CDK4/6 inhibitors are increasingly becoming a promising cancer therapy evident with approved drugs such as palbociclib, ribociclib, and abemaciclib, etc. In this article, we explore the biological importance of CDK4/6 in cancer therapy, the development of resistance to monotherapy, and a short overview of PROTAC (Proteolysis Targeting Chimera), a unique and pioneering technique for degrading CDK4/6 enzymes. Overall, our prime focus is to discuss novel CDK4/6 inhibitors with diverse chemical classes and their correlation with computational studies.
- 1 September 2021
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 11 (47) , 29227-29246
Open AccessCDK4/6 inhibitors: a brief overview and prospective research directions
The discovery of cyclin-dependent kinases (CDK) and their mechanism in regulating the cell cycle process was considered a game-changer in cancer therapy. Cell cycle arrest and apoptosis were both triggered by their inhibition. The CDK4/6 complex acts as a checkpoint during the cell cycle transition from cell growth (G1) to DNA synthesis (S) phase and its deregulation or overexpression induces abnormal cell proliferation and cancer development. Consequently, targeting CDK4/6 has been proposed as a paradigm shift in the anticancer approach. The design and development of effective CDK4/6 inhibitors are increasingly becoming a promising cancer therapy evident with approved drugs such as palbociclib, ribociclib, and abemaciclib, etc. In this article, we explore the biological importance of CDK4/6 in cancer therapy, the development of resistance to monotherapy, and a short overview of PROTAC (Proteolysis Targeting Chimera), a unique and pioneering technique for degrading CDK4/6 enzymes. Overall, our prime focus is to discuss novel CDK4/6 inhibitors with diverse chemical classes and their correlation with computational studies.